ASX healthcare shares were a mixed basket this past financial year.
After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January.
The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around 5% into the red for the 12 months to June 30. It traded in sideways territory from January to June.
These three healthcare shares are worthy of note. Let's take a look at each one.
CSL Limited (ASX: CSL)
The biotech giant is a natural on this list. It suffered a similar fate to the wider sector on the charts in FY22.
After soaring to a 52-week high price of $318 on 24 November, ASX investors sold CSL down to a 52-week low of $243 per share by February.
CSL announced its acquisition offer for Vifor Pharma in December last year. It issued US$4 billion of bonds in the US debt capital markets to finance the transaction.
The six issued notes pay a coupon ranging from 3.85% to 4.95% per annum and range from five years to 40 years in tenor.
The CSL share price finished FY22 in a bullish uptrend that has continued into the new financial year. It is down 3.5% in 2022 so far and trading at $285.66 at the time of writing.
ResMed CDI (ASX: RMD)
Sleep treatment company ResMed recognised a series of losses in FY22.
ResMed reversed out of a bullish uptrend in late 2021. The ResMed share price fell from a high of $40.28 on 13 September to a 52-week low of $27.63 in May.
Despite its struggles, several analysts rate the ResMed share price a buy. Fundamentally, they say, the company is strong, and its long-term outlook is attractive.
Morgans is bullish on ResMed and says "nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform."
Meanwhile, analysts at HB Insights are also bullish. They reckon a product recall by ResMed's competitor is a boon for the company.
This ASX healthcare share is trading down 0.92% today at $32.20.
Immutep Ltd (ASX: IMM)
Finally, Immutep is worth a mention in this list. The developer of LAG-3 immunotherapy cancer treatments had a choppy year and landed deep in the red.
Nevertheless, it released several updates across the 12 months regarding its flagship label, known as etfi.
Etfi gained more clinical trial momentum in FY22. It was most recently recognised at the American Society of Clinical Oncology 2022 special edition.
However, ASX investors appear to have overlooked this clinical progress, and have traded the Immutep share price down to a 52-week low of 29 cents on 30 June.
It has now levelled back up to trade at 32 cents.
